W METRO-MINNEAPOLIS COMMUNITY CLINICAL ONCOLOGY PROGRAM

West Metro-Minneapolis社区临床肿瘤学项目（WMMCCOP） 代表一个由七家医院组成的财团，通过其国家癌症研究所资助的 社区医院肿瘤计划（“CHOP”）和业务CCOP， 已经开发出一种管理癌症患者的通用方法， 并有一个既定的机制，进入和跟踪病人 治疗和癌症控制方案。 该财团有一个 全社区计算机化数据管理系统（TUMORS/CHOP-DS） 前瞻性数据收集。 社区提供6个HMO计划，所有 这七家联合医院都有代表。 在一起， 这七家医院平均每家有4700名新的分析性癌症患者， 年 代表肿瘤学的34名核心研究者， 血液学、免疫学、放射肿瘤学、泌尿学和结直肠 外科，在癌症项目开发方面进行了广泛的合作， 协议管理 WMMCCOP的工作人员在以下方面有资格并接受过培训： 肿瘤学和数据管理，并参与了 当前的程序结构和操作。 在最近一 在NCI资助的一年（6/88-5/89），WMMCCOP纳入了1069例患者（134 治疗信用/54癌症控制信用到NCI批准的研究）。 WMMCCOP打算：维持一个区域范围的社区和医院 为社会提供最新进展， 癌症控制和治疗。 这将通过扩张来实现 目前的财团，包括新的医院目前没有 参与WMMCCOP，增加初级保健的参与 医生和外科医生;提供专业知识，资源， 制定、实施和评估临床癌症的人口基础 通过与NCI，ECOG，NSABP， FCCC，明尼苏达州卫生部和M.D.安德森;改善和 扩展当前的WMMCCOP数据管理和通信系统， 增加调查人员参与的数量和水平 权责发生制、项目运营和研究基础活动;鼓励 少数群体的参与;增加专业和非专业社区 对CCOP的认识和临床癌症试验的益处。 期间 在本赠款期内运作的第一年，WMMCCOP调查人员 计划在NCI批准的癌症治疗和控制上累积250个学分 研究，超过了这两类研究的最低要求。

The West Metro-Minneapolis Community Clinical Oncology Program (WMMCCOP) represents a consortium of seven hospitals which, through its NCI-funded Community Hospital Oncology Program ("CHOP") and operational CCOP, has already developed a common approach to the management of cancer patients and has an established mechanism for entering and following patients on treatment and cancer control protocols. The consortium has a community-wide computerized data management system (TUMORS/CHOP-DS) capable of prospective data collection. The community offers 6 HMO programs, all of which are represented among these seven consortium hospitals. Together, the seven hospitals see an average of 4700 new analytic cancer patients per year. The thirty-four core investigators, representing oncology, hematology, immunology, radiation oncology, urology, and colorectal surgery, have worked extensively together on cancer program development and protocol management. The WMMCCOP staff is qualified and trained in oncology and data management, and has been involved in the development of the current program structure and operation. During the most recent NCI-funded grant year (6/88-5/89), the WMMCCOP entered 1069 patients (134 treatment credits/54 cancer control credits onto NCI-approved studies). The WMMCCOP intends to: sustain a region wide community and hospital consortium which provides the community with the most recent advances in cancer control and treatment. This will be accomplished through expansion of the current consortium to include new hospitals not currently participating in the WMMCCOP, increased involvement of primary care physicians and surgeons; providing the expertise, resources, and large population base to develop, implement and evaluate clinical cancer treatment and control trials through affiliation with the NCI, ECOG, NSABP, FCCC, the Minnesota Department of Health, and M.D. Anderson; improve and expand the current WMMCCOP data management and communication system to increase the number and level of participation of the investigators in accrual, program operations and research base activities; encourage minority group participation; increase the professional and lay community awareness of the CCOP and benefits of clinical cancer trials. During the first year of operation under this grant period, WMMCCOP investigators intend to accrue 250 credits onto NCI-approved cancer treatment and control studies, exceeding the minimum requirements for both types of studies.